8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-08-13 AccNo: 0001213900-26-088701 Size: 260 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Filed: 2026-07-22 AccNo: 0001213900-26-080474 Size: 261 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-13 AccNo: 0001213900-26-088701 Size: 260 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarBluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(1.12) per share. This is a 80.14 percent increase over losses of $(5.64) per share from the same period last year.
Read original at benzingaArista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares rose 13% in pre-market trading.
Read original at benzingaBluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the successful completion of patient enrollment in its
Read original at benzinga